论文部分内容阅读
目的：开发利用正常胎儿脐血作为ＬＡＫ细胞免疫治疗的细胞来源。方法：用含ｒＩＬ２的完全培养基培养脐血淋巴因子激活的杀伤细胞（脐血ＬＡＫ），并作脐血ＬＡＫ对肿瘤细胞的杀伤率。结果：６例培养２５ｄ的脐血ＬＡＫ细胞平均扩增速度为１３４．３９倍，在效靶比例为２０∶１时，培养１０ｄ的脐血ＬＡＫ细胞作用于不同的肿瘤细胞（黑色素瘤２例，卵巢囊腺癌１例及其癌性腹水１份，大网膜转移性腺癌１例及癌性腹水１份），杀伤率３８．１３％～５８．７０％。结论：脐血ＬＡＫ对肿瘤细胞有较强的杀伤作用，提示脐血可作为ＬＡＫ细胞的重要来源。
OBJECTIVE: To develop and utilize the normal fetal cord blood as a cell source for immunotherapy of LAK cells. Methods: Umbilical cord blood lymphokine-activated killer cells (cord blood LAK) were cultured with complete medium containing rIL 2, and cytotoxicity of LAK to tumor cells was determined. Results: The average rate of LAK cells in 6 cases cultured for 25 days was 134.39 times. When the effective target ratio was 20:1, LAK cells cultured for 10 days were used in different tumor cells (2 cases of melanoma, 1 case of ovarian cystadenocarcinoma and 1 case of its cancerous ascites, 1 case of omental metastatic adenocarcinoma and 1 case of cancerous ascites. The killing rate was 38.13% -58.70%. Conclusion: Umbilical cord blood LAK has a strong killing effect on tumor cells, suggesting that cord blood can be an important source of LAK cells.